| Extracellular matrix remodeling in atrial fibrosis: mechanisms and implications in atrial fibrillation. | |
| | |
MedLine Citation:
|
PMID: 19751740 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Atrial fibrosis has been strongly associated with the presence of heart diseases/arrhythmias, including congestive heart failure (CHF) and atrial fibrillation (AF). Inducibility of AF as a result of atrial fibrosis has been the subject of intense recent investigation since it is the most commonly encountered arrhythmia in adults and can substantially increase the risk of premature death. Rhythm and rate control drugs as well as surgical interventions are used as therapies for AF; however, increased attention has been diverted to mineralocorticoid receptor (MR) antagonists including spironolactone as potential therapies for human AF because of their positive effects on reducing atrial fibrosis and associated AF in animal models. Spironolactone has been shown to exert positive effects in human patients with heart failure; however, the mechanisms and effects in human atrial fibrosis and AF remain undetermined. This review will discuss and highlight developments on (i) the relationship between atrial fibrosis and AF, (ii) spironolactone, as a drug targeted to atrial fibrosis and AF, as well as (iii) the distinct and common mechanisms important for regulating atrial and ventricular fibrosis, inclusive of the key extracellular matrix regulatory proteins involved. |
| | |
Authors:
|
Jason Pellman; Robert C Lyon; Farah Sheikh |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review Date: 2009-09-12 |
Journal Detail:
|
Title: Journal of molecular and cellular cardiology Volume: 48 ISSN: 1095-8584 ISO Abbreviation: J. Mol. Cell. Cardiol. Publication Date: 2010 Mar |
Date Detail:
|
Created Date: 2010-02-17 Completed Date: 2010-05-14 Revised Date: 2012-02-15 |
Medline Journal Info:
|
Nlm Unique ID: 0262322 Medline TA: J Mol Cell Cardiol Country: England |
Other Details:
|
Languages: eng Pagination: 461-7 Citation Subset: IM |
Copyright Information:
|
2009 Elsevier Ltd. All rights reserved. |
Affiliation:
|
Department of Medicine, University of California-San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0613, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Angiotensin II Type 1 Receptor Blockers
/
therapeutic use Animals Atrial Fibrillation / drug therapy, metabolism*, physiopathology Extracellular Matrix / metabolism* Fibrosis / drug therapy, metabolism*, physiopathology Heart Atria / metabolism*, pathology, physiopathology Humans Signal Transduction / drug effects Spironolactone / therapeutic use |
| Grant Support | |
ID/Acronym/Agency:
|
P41 RR004050-197140/RR/NCRR NIH HHS; P41 RR004050-208540/RR/NCRR NIH HHS; R01 HL095780-01/HL/NHLBI NIH HHS; R01 HL095780-01S1/HL/NHLBI NIH HHS; R01 HL095780-04/HL/NHLBI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Angiotensin II Type 1 Receptor Blockers; 52-01-7/Spironolactone |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Preservation of mitochondrial function with cardiopulmonary resuscitation in prolonged cardiac arres...
Next Document: Matricryptic sites control tissue injury responses in the cardiovascular system: relationships to pa...